Valence8 US’s Nektar Therapeutics NKTR Stock Holding History

Valence8 US’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,740	Closed	-$33.9K	–	45
2024 Q3	$33.9K	Buy	+1,740	New	+$33.2K	0.01%	60

Other funds holding NKTR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Valence8 US's NKTR Position: Q4 2024 in Review

Valence8 US sold out of Nektar Therapeutics (NKTR) in Q4 2024, closing a stake of 1,740 shares — an estimated $33.9K sold.

Valence8 US first reported a position in NKTR in Q3 2024 and held it in 1 quarter. The position peaked at $33.9K in Q3 2024. 143 funds tracked by Wall St. Rank hold NKTR as of Q4 2024.

Valence8 US reported no remaining Nektar Therapeutics position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 1,740 Nektar Therapeutics shares in Q4 2024, an estimated $33.9K.
Valence8 US first reported a position in Nektar Therapeutics in Q3 2024 and held it in 1 quarter.
Valence8 US's Nektar Therapeutics position peaked at $33.9K in Q3 2024.
143 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.